Roche pharmaceutical company announced the approval of their application for their Port Delivery System (PDS) as an alternative to eye injections for the treatment of wet age-related macular degeneration (AMD).
Roche is looking for marketing approval for the delivery of ranibizumab by PDS to treat wet AMD. The new device offers a continuous therapeutic dose of ranibizumab to the eye in place of regular eye injections. Approximately the size of a grain of rice, the PDS is a refillable eye implant that can be refilled every six months via a specially designed needle.
Upon approval, the device would offer patients an alternative to the current therapy of monthly eye injections. The FDA anticipates making a decision regarding approval by October 23, 2021.
For people dealing with the dry form of macular degeneration, VisiVite offers several AREDS2 supplements that are based on the second age-related eye disease study.